Grantham, Mayo, Van Otterloo & Co (GMO)’s Apogee Therapeutics APGE Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.2M	Buy	+137,395	New	+$12.4M	0.04%	191

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s APGE Position: Q2 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 137,395 shares worth $18.2M. The stake represents 0.04% of the portfolio and ranks #191 among its holdings.

288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Grantham, Mayo, Van Otterloo & Co (GMO) held 137,395 shares of Apogee Therapeutics worth $18.2M as of Q2 2026.
Apogee Therapeutics was a new Grantham, Mayo, Van Otterloo & Co (GMO) position in Q2 2026.
Apogee Therapeutics made up 0.04% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q2 2026, its #191 holding.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2026, filed 13 Aug 2026.